Every 8-K that LIPELLA PHARMS INC (LIPO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LIPO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIPO filings page.
Lipella Pharmaceuticals Inc. is operating under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Western District of Pennsylvania, Case No. 26-20879-CMB, after filing a voluntary petition on March 30, 2026.
On May 14, 2026, the company entered into an Asset Purchase Agreement with XRAIY under which XRAIY agreed to purchase substantially all of Lipella’s assets. The Bankruptcy Court authorized and approved this sale and the Asset Purchase Agreement pursuant to section 363 of the Bankruptcy Code by order dated June 4, 2026, with the order and agreement provided as exhibits.
The company cautions that trading in its common stock while the Chapter 11 case is pending is highly speculative and poses substantial risks, and that trading prices may bear little or no relationship to the actual recovery, if any, by holders of its common stock.
Lipella Pharmaceuticals Inc. has filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Western District of Pennsylvania. The company plans to pursue a Section 363 sale process intended to maximize value for creditors.
Lipella expects to seek customary first-day relief so it can continue day-to-day operations, including maintaining cash management systems and paying employee wages and benefits in the ordinary course. The company also cautions that trading in its common stock during the Chapter 11 cases is highly speculative and that trading prices may bear little or no relationship to any ultimate recovery for shareholders.
Lipella Pharmaceuticals Inc. reported that board member Dr. Lori A. Birder resigned from its Board of Directors, effective immediately on February 3, 2026. The company stated that her resignation was not due to any disagreement regarding its operations, policies, or practices, indicating a routine governance change rather than a dispute-driven departure.
Lipella Pharmaceuticals Inc. announced a planned board change. On October 20, 2025, Dr. Naoki Yoshimura notified the company of his intention to retire from the Board of Directors, effective December 31, 2025.
The company stated that Dr. Yoshimura’s decision to retire did not result from any disagreement with the company on matters related to operations, policies, or practices.
Lipella Pharmaceuticals Inc. announced that Dr. Michael ChancellorOctober 3, 2025, with the retirement to be effective on December 4, 2025. The company states that Dr. Chancellor’s decision to retire did not result from any disagreement regarding its operations, policies, or practices, indicating an orderly leadership transition rather than a dispute-driven departure.
Lipella Pharmaceuticals Inc. reported positive final results from a completed Phase 2a multicenter, dose‑ranging study of LP-10, a proprietary liposomal tacrolimus oral rinse, in adults with symptomatic oral lichen planus (OLP). The study met its primary safety endpoint and showed statistically significant improvements across all efficacy measures at the 4‑week timepoint in all three dose groups (0.25 mg, 0.5 mg, and 1.0 mg).
The trial enrolled 27 adults with biopsy‑confirmed symptomatic OLP at five U.S. sites; 81.5% were female, the median age was 62 years, disease duration ranged from 1 to 28 years, and all had failed standard therapies such as topical corticosteroids. All patients completed the 4‑week treatment, no serious adverse events were reported, systemic exposure was minimal with 76% of tacrolimus blood measurements below 1.0 ng/mL, and treatment‑related side effects were mild to moderate, mainly dry mouth in 18.5% of patients.
Investigator assessments showed clear reductions in ulceration and erythema, pain and sensitivity improved significantly on numerical rating scales, and patient‑reported symptoms on the OLP Symptom Severity Measure improved, with benefits sustained through a two‑week follow‑up. The company states these results support LP‑10’s potential to become the first FDA‑approved therapy for OLP, which affects an estimated 6 million Americans, and is preparing Phase 2b development, manufacturing scale‑up, and potential strategic partnerships.
Lipella Pharmaceuticals (LIPO) filed an 8-K announcing its delisting from the Nasdaq Capital Market. The company released a stockholder letter from CEO Jonathan Kaufman addressing the delisting and outlining plans to relist on a national exchange. The filing includes a press release and stockholder letter as exhibits 99.1 and 99.2.
As an emerging growth company, Lipella provided standard forward-looking statements cautioning that actual outcomes may differ from expectations regarding product candidate development and relisting efforts.
Lipella Pharmaceuticals Inc. ("LIPO") has been formally delisted from the Nasdaq Capital Market. On 20 June 2025 the company received a Nasdaq Hearings Panel letter, dated 17 June 2025, exercising discretionary authority under Listing Rule 5100 to delist the company’s common stock. The Panel cited two rule violations that arose from private placements conducted between December 2024 and March 2025: (i) failure to secure prior shareholder approval for issuances exceeding 20 % of outstanding shares below the minimum price (Rule 5635(d)), and (ii) actions that disparately reduced or restricted existing shareholders’ voting rights (Rule 5640).
Trading in LIPO shares was suspended at the market open on 20 June 2025. The company expects to file Form 25 with the SEC to formally remove its listing. As of the suspension date, the common stock now trades on the OTC Markets Group’s Pink Market under the existing ticker "LIPO".
The 8-K also furnishes a press release (Exhibit 99.1) announcing the delisting. Management emphasises that forward-looking statements in the filing involve significant risk and that the company is evaluating all market alternatives for future listing; however, no concrete remediation plan or timeline is provided.